Amous Y, Isefan S, Hamarsheh K, Hijaz H, Amer R, Shawahna R
BMC Urol. 2024; 24(1):199.
PMID: 39272085
PMC: 11396118.
DOI: 10.1186/s12894-024-01587-5.
Hamshari S, Sholi S, Jamous M, Taha A, Aghbar A, Abu Alwafa R
J Family Med Prim Care. 2024; 13(8):3195-3202.
PMID: 39228634
PMC: 11368317.
DOI: 10.4103/jfmpc.jfmpc_231_24.
Oliveira A, de Oliveira M, Monica F, Antunes E
Biomedicines. 2024; 12(5).
PMID: 38790901
PMC: 11118115.
DOI: 10.3390/biomedicines12050939.
Hwang S, Yun J, Cho S, Min K, Kim J, Kwon H
World J Mens Health. 2024; 43(1):166-173.
PMID: 38606860
PMC: 11704167.
DOI: 10.5534/wjmh.230303.
Liu T, Pascal L, Bauer S, Miles H, Panksepp J, Lloyd G
J Gerontol A Biol Sci Med Sci. 2024; 79(6.
PMID: 38198648
PMC: 11079951.
DOI: 10.1093/gerona/glae007.
Selenium in combination with a tomato lipid extract as a therapy for benign prostatic hyperplasia and its alterations in rats with induced BPH.
Arias-Chavez D, Mailloux-Salinas P, Aparicio J, Campos-Perez E, Medina-Campos O, Pedraza-Chaverri J
J Cell Mol Med. 2023; 27(20):3147-3156.
PMID: 37726932
PMC: 10568668.
DOI: 10.1111/jcmm.17903.
A Spectrum of Age- and Gender-Dependent Lower Urinary Tract Phenotypes in Three Mouse Models of Type 2 Diabetes.
MacIver B, Bien E, de Oliveira M, Hill W
Metabolites. 2023; 13(6).
PMID: 37367868
PMC: 10304708.
DOI: 10.3390/metabo13060710.
Effects of the CB1 receptor antagonists AM6545 and AM4113 on metabolic syndrome-induced prostatic hyperplasia in rats.
Eid B, Neamatallah T, Binmahfouz L, Bagher A, Alamoudi A, Aldawsari H
Biomol Biomed. 2023; 23(6):1069-1078.
PMID: 37212036
PMC: 10655885.
DOI: 10.17305/bb.2023.9173.
Obesity, metabolic health, and urological disorders in adults: a nationwide population-based study.
Kim J, Lee Y, Han K, Han J
Sci Rep. 2021; 11(1):8687.
PMID: 33888807
PMC: 8062508.
DOI: 10.1038/s41598-021-88165-z.
Adult obesity complications: challenges and clinical impact.
Ansari S, Haboubi H, Haboubi N
Ther Adv Endocrinol Metab. 2020; 11:2042018820934955.
PMID: 32612803
PMC: 7309384.
DOI: 10.1177/2042018820934955.
Menorrhagia and Uterine Volume Associated with Lower Urinary Tract Symptoms in Patients with Adenomyosis.
Li T, Xu X, Dai Y, Zhang J, Lang J, Leng J
Chin Med J (Engl). 2017; 130(13):1552-1556.
PMID: 28639570
PMC: 5494918.
DOI: 10.4103/0366-6999.208232.
Is diabetes mellitus associated with clinical outcomes in aging males treated with transurethral resection of prostate for bladder outlet obstruction: implications from Taiwan Nationwide Population-Based Cohort Study.
Lin Y, Hou C, Chen T, Juang H, Chang P, Yang P
Clin Interv Aging. 2017; 12:535-541.
PMID: 28356725
PMC: 5360412.
DOI: 10.2147/CIA.S126207.
Path of translational discovery of urological complications of obesity and diabetes.
Daneshgari F, Liu G, Hanna-Mitchell A
Am J Physiol Renal Physiol. 2017; 312(5):F887-F896.
PMID: 28052873
PMC: 6109798.
DOI: 10.1152/ajprenal.00489.2016.
Ejaculatory dysfunction in the treatment of lower urinary tract symptoms.
DeLay K, Nutt M, McVary K
Transl Androl Urol. 2016; 5(4):450-9.
PMID: 27652217
PMC: 5002000.
DOI: 10.21037/tau.2016.06.06.
NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.
Austin D, Strand D, Love H, Franco O, Grabowska M, Miller N
Prostate. 2016; 76(11):1004-18.
PMID: 27197599
PMC: 4912960.
DOI: 10.1002/pros.23195.
Obesity-initiated metabolic syndrome promotes urinary voiding dysfunction in a mouse model.
He Q, Babcook M, Shukla S, Shankar E, Wang Z, Liu G
Prostate. 2016; 76(11):964-76.
PMID: 27040645
PMC: 4946024.
DOI: 10.1002/pros.23185.
Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.
Vignozzi L, Gacci M, Maggi M
Nat Rev Urol. 2016; 13(2):108-19.
PMID: 26754190
DOI: 10.1038/nrurol.2015.301.
Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options.
Saad F, Yassin A, Haider A, Gooren L
Arab J Urol. 2015; 9(2):147-52.
PMID: 26579287
PMC: 4150581.
DOI: 10.1016/j.aju.2011.06.003.
Metabolic syndrome does not impair the response to alfuzosin treatment in men with lower urinary tract symptoms: a double-blind, randomized, placebo-controlled study.
Altin S, Ozan T, Ilhan S, Ilhan N, Onur R
Turk J Urol. 2015; 41(3):125-31.
PMID: 26516595
PMC: 4608450.
DOI: 10.5152/tud.2015.89656.
Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study.
Robinson D, Garmo H, Stattin P, Michaelsson K
PLoS One. 2015; 10(10):e0140598.
PMID: 26469978
PMC: 4607359.
DOI: 10.1371/journal.pone.0140598.